Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for romosozumab

  1. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  2. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: TBC

  3. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

  4. Thousands of people set to benefit from first new treatment for osteoporosis for over a decade

    Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment – romosozumab – after NICE recommended it for people after menopause in final draft guidance published today (Friday 1 April) by NICE.